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Abstract
Background: Changes in gene expression in pancreatic beta-cells from type 2 diabetes (T2D) should provide insights into
their abnormal insulin secretion and turnover.
Methodology/Principal Findings: Frozen sections were obtained from cadaver pancreases of 10 control and 10 T2D human
subjects. Beta-cell enriched samples were obtained by laser capture microdissection (LCM). RNA was extracted, amplified and
subjected to microarray analysis. Further analysis was performed with DNA-Chip Analyzer (dChip) and Gene Set Enrichment
Analysis (GSEA) software. There were changes in expression of genes linked to glucotoxicity. Evidence of oxidative stress was
provided by upregulation of several metallothionein genes. There were few changes in the major genes associated with cell
cycle, apoptosis or endoplasmic reticulum stress. There was differential expression of genes associated with pancreatic
regeneration, most notably upregulation of members of the regenerating islet gene (REG) family and metalloproteinase 7
(MMP7). Some of the genes found in GWAS studies to be related to T2D were also found to be differentially expressed.
IGF2BP2, TSPAN8, and HNF1B (TCF2) were upregulated while JAZF1 and SLC30A8 were downregulated.
Conclusions/Significance: This study made possible by LCM has identified many novel changes in gene expression that
enhance understanding of the pathogenesis of T2D.
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Introduction
Pancreatic beta-cells play a central role in the development
and progression of type 2 diabetes (T2D) [1]. In subjects
predisposed to T2D beta-cell dysfunction occurs early in the
course of the disease [1,2], with deterioration occurring during
the transition from the ‘‘normal’’ state to impaired glucose
tolerance and then to frank diabetes [1,3]. Beta-cell dysfunc-
tion is now accepted to be associated with reduced beta-cell
mass [4,5], which has even been shown to be present in the
state of impaired glucose tolerance [4]. Beta–cell abnormalities
likely result from a combination of genetic and environmental
factors. This reduction in beta-cell mass could be caused by
either inadequate birth of beta-cells, increased death by
apoptosis or necrosis, or some combination of the two [6].
The development of secretory dysfunction is closely tied to
rising glucose levels and presumed to be caused by the process
of glucotoxicity [1].
Genome-wide association studies and single gene studies have
identified polymorphisms within genes potentially influencing the
beta–cell development and function [7]. However, the character-
istics of gene expression in beta-cells of T2D subjects, which
determines the cell phenotype, are largely unknown; only a few
studies have evaluated the gene expression of islets isolated from
T2D subjects [8–15]. A limitation of these studies is that they have
been performed on isolated human islet preparations, which
contain substantial numbers of islet non-beta cells, duct cells, and
acinar cells. In addition, the islets have been studied after the
trauma of the isolation procedure that causes changes in gene
expression [16–18]. These limitations can be overcome by
studying beta–cell enriched tissue dissected from the pancreatic
tissue directly, using the laser capture microdissection (LCM)
technique [18,19].
In the present study we performed the LCM on ten control and
ten T2D subjects; messenger RNA was analyzed by microarray
and real-time PCR was performed on selected genes. The results
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11499showed a variety of alterations in gene expression of beta–cells
obtained from T2D donors.
Results and Discussion
Clinical characteristics
Pancreas specimens from ten non-diabetic and ten T2D subjects
were studied. Their clinical characteristics can be found in Table 1.
Approach to LCM and islet anatomy
It is important to point out that LCM was used selectively in
that islets were chosen that had relatively well defined patches of
beta-cells with endogenous immunofluorescence. It was impor-
tant to do this because human islets are known have clumps of a
and d cells in the islet core [6], which means that great care must
be taken with LCM to avoid the non beta-cells. Thus, there are
some populations of beta-cells that cannot be collected for
geographical reasons. We expect that these selected beta-cells are
representative of beta-cells throughout the pancreas but must be
cautious about this assumption. It cannot be excluded that beta-
cells in islets of different size and locations may be subjected to
different paracrine and environmental influences that could alter
gene expression. Another point is that the endogenous immuno-
fluorescence of the beta-cells may emanate from lipofuscin, which
is thought to accumulate as beta-cells age [20]. Thus, it is possible
that the beta-cells collected with LCM are older than the overall
population. However they would be comparable in the two
groups since no differences in the intensity of immunofluoresence
could be discerned between beta-cells of control versus T2D
pancreases.
The 10 T2D pancreases had the range of pathology expected
for T2D. Amyloid could be found in some islets in most of the
pancreases, as was expected from previous observations [21,22].
Moreover, much islet variation was seen, which included islets
with fibrosis, islets with high non-beta-/beta-cell ratios, and a
range of islet size. Extracellular lipid deposits were not particularly
noticeable. We did not stain for alpha-cells, so we do not know the
alpha-cell/beta-cell ratio specifically, but we had the impression
that non-beta-cell/beta-cell ratio is up, as is well described by
many including MacLean and Ogilvie in 1955 [23] and then more
recently by Clark et al [24] and Yoon et al [25]. As was also done
for the control pancreases, relatively well defined patches of beta
cells were chosen for LCM. Thus, for the T2D pancreases, this
means that care was taken to avoid islets with amyloid and/or
fibrosis.
Expression profiles in samples obtained from T2D donors
compared to control donors
By using the lower confidence bound (LCB) parameter at the
cutoff of 1.2, DNA-Chip Analyzer (dChip) software identified
2,062 differentially expressed probe sets, corresponding to 1,920
transcripts. Among them, 1,203 transcripts were upregulated and
717 were downregulated in samples obtained from T2D subjects
as compared to non-diabetic controls. Using the p value
parameter, 7,164 probe sets, corresponding to 6,384 transcripts
were differentially expressed at p,0.05 (3,464 transcripts
upregulated and 2,920 downregulated), whereas 2,133 probe sets,
corresponding to 1,870 transcripts were different at p,0.01 (1006
upregulated and 864 downregulated). Hierarchical clustering
analysis of differentially expressed genes showed a clear separation
between diabetic and non-diabetic samples (Fig. 1).
As reported in Figure 2, the Principal Component Analysis
showed that samples run at the Genomic Core facilities of the
Joslin Diabetes Center and the Massachusetts General Hospital, at
two different times, clustered in two different groups. All data
are MIAME compliant and the row data have been deposited
in a MIAME compliant database (GEO, accession numbers:
GSE20966).
Approach to analysis
Most of the analysis was done with dChip software. We first
looked at groups of genes thought to be important for the beta-cell
abnormalities known to occur in T2D. They were grouped into
categories of function. Other genes were included because they
seemed to be good candidates to be important; some were
differentially expressed, others were not. Clusters of genes with
common function were assessed with GSEA. In assessing the signal
strength of arrays as determined by dChip, the strength can be a
general indicator of the abundance of the mRNA, but caution
must be used for interpretation. Two major variables: the
amplification process will change the abundance of the transcripts
and low signal strength may results from inefficient probes. We
know that some of the high strength signals are incorrect. For
example, the array signal strength for insulin and glucagon was
similarly high, yet when unamplified mRNA obtained with LCM
was assessed with quantitative PCR, the insulin transcript levels
were far higher than glucagon [18]. Nonetheless, the signals are
very consistent for comparing groups such as samples from T2D
versus controls. Moreover, the general strength of the signals
provides insights into the relative strength of various isoforms. For
example creatine kinase, brain (CKB), which may be important for
glucose stimulated insulin secretion (GSIS), was highly expressed
while the muscle form (CKM) was hardly expressed at all (Table
S1).
Islet hormones and receptors
The array signals for insulin (INS), glucagon (GCG), somato-
statin (SST) and IAPP were all very high and only IAPP was
differentially expressed, downwards (Table S2). These signals
clearly do not provide accurate information about the actual
abundance of message, as we have shown previously using PCR
on samples collected by LCM [18]. It seems this is particularly a
problem when the message is very highly expressed. Nonetheless,
the reduced expression of IAPP is not surprising because similar
reduction has been found in rodents with diabetes, which is
Table 1. Clinical characteristics of type 2 diabetic and control
subjects.
Controls Type 2 diabetic donors
Gender (males/females) 6/4 7/3
Age (years) 60656 7 67
BMI (Kg/m
2) 30.566.5 30.966.2 (n=9)
Cause of death 8 CVD, 1 TR, 1 SA 8 CVD, 1 TR
Known diabetes duration
(years)
- 5.362.3 (n=7)
Anti-diabetes therapy - Oral (n=6); insulin (n=3)
All donors were White. Data are expressed as mean 6 standard deviation (SD).
The two groups were different for age (p=0.019) and comparable for BMI
(p=0.917). The duration of diabetes was 5.362.3 years (n=7, data of 3 diabetic
donors are not available); three diabetic subjects were insulin treated and six
received oral anti-diabetic therapy, information related to the anti-diabetic
treatment of one subject is not available.
CVD: cardiovascular disease; TR:trauma; SA: surgical accident.
doi:10.1371/journal.pone.0011499.t001
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expression was found for either the receptors for glucagon
(GCGR) or GLP1 (GLP1R); the signals for the gastric inhibitory
polypeptide receptor (GIPR) were very weak.
Islet transcription factors
In our previous studies with the rat partial pancreatectomy
model, with multiplex PCR on isolated islets we found
downregulation of pdx1, nkx6.1, pax6, neurod and hnf1alpha
[26]. In the present study there was down regulation of HNF1A
(TCF1) but no change in the expression of NKX6-1 or
NEUROD1 (Table S2). PAX6 was upregulated. Unexpectedly,
PDX1 was upregulated but the signal strength was low compared
to other transcription factors. This might be due to low
amplification efficiency of PDX1 transcript or inefficient binding
of the transcript to the corresponding probe set. Other
transcription factors not changed included NKX2-2, PAX4,
HNF4A, neurogenin 3 (NEUROG3), and MAFB. PAX6 and
ARX, which are normally found in alpha-cells [27], were
upregulated, which raises the question as to whether the beta-
cells of T2D developed some alpha-cell characteristics or whether
the LCM of the T2D tissue somehow collected more alpha-cell
tissue. It is possible that an increase in the ratio of alpha-cells to
beta-cells might have made it more likely that a few more alpha-
cells were contained in the material captured from the T2D
pancreases. However, great care was taken to restrict the LCM to
fluorescent beta-cells. If there were some inadvertent inclusions,
one might have expected variability of PAX6 and ARX expression
among the T2D pancreases, but the consistency was similar to that
seen in the controls. Another possibility is that beta-cells in T2D
express alpha-cell genes more highly. Others and we have found
that some single beta-cells obtained by flow cytometry have a low
level of glucagon gene expression [28,29]. This becomes especially
interesting with the recent report by the group of Herrera that
alpha-cells may be able to transdifferentiate into beta-cells during
regeneration [30].
Figure 1. Hierarchical clustering of differentially expressed genes. Hierarchical clustering analysis of genes differentially expressed was
performed using dChip software. The distances among high-dimensional expression profiles are represented as a dendrogram that arranges the
clustered samples in terms of similarity to one another. The analysis showed a clear separation in two groups of samples from diabetic and control
subjects. The analysis divides samples into groups with similar patterns in gene expression data (a p value of less than 0.05 was considered).
doi:10.1371/journal.pone.0011499.g001
Figure 2. Principal Component Analysis. Principal Component Analysis (PCA) reduces the number of variables and sort microarray experiments
into groups. The analysis was performed using Rosetta Resolver software, version 7.2.2.0, with all the array data after normalization by dChip
software. Three principal components were generated and plotted; each individual point identifies a single expression profile. The first principal
component (PC1) that captures the maximum amount of variation between samples determined the clustering of samples into two groups: one
group (12 samples, left) was run at the Joslin Diabetes Center Genomic Core facility, the other group (8 samples, right) was run at the Genomic Core
facility of the Massachusetts General Hospital. Variations were also observed along the second principal component (PC2) and the third principal
component (PC3). The purple and brown dots refer to samples from diabetic subjects run at the Joslin Diabetes Center and Massachusetts General
Hospital, respectively; the blue and green dots refer to control subject samples run at the Joslin Diabetes Center and Massachusetts General Hospital.
doi:10.1371/journal.pone.0011499.g002
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Because beta-cells in a diabetic environment have profoundly
abnormal GSIS, components of glucose metabolism pathways that
are linked to secretion can be expected to be abnormal in T2D.
The expression results of noteworthy genes are shown in Table S1.
With regard to glucose transport, GLUT2 was downregulated in
the T2D sample while GLUT1 was unchanged. This is of interest
because while GLUT2 is thought to be important for rodents,
evidence suggests that GLUT1 is largely responsible for glucose
transport in human beta-cells [31]. For the glycolytic enzymes, no
change was seen in the expression of glucokinase (GCK). Three
forms of phosphofructokinase (PFKM, P and L) were highly but
not differentially expressed. Aldolase B (ALDOB) was highly
expressed and upregulated while enolase 1, alpha (ENO1) was
modestly expressed and downregulated. Lactate dehydrogenase A
(LDHA), which normally has very low expression in beta-cells [32]
was upregulated. Pyruvate carboxylase (PC), which is highly
expressed in rodent islets [26,33], had low signal strength and no
differential expression.
For gluconeogenesis, which is thought to be negligible in normal
beta-cells, phosphoenolpyruvate carboxykinase 1 (PCK1) was
upregulated, while the Fructose-1, 6-bisphosphatase (FBP2) and
glucose-6-phosphatase (G6PC and G6PC3) enzymes genes had
low signal strength and no differential changes. The mitochondrial
enzyme dihydrolipoamide dehydrogenase (DLD), which is the E3
component of pyruvate dehydrogenase complex, was downregu-
lated. Of enzymes of the tricarboxylic acid cycle, the only
potentially interesting changes were a modest reduction in
aconitase 2 (ACO2) and an increase of mitochondrial succinate
dehydrogenase complex, subunit C (SDHC). There was no
differential expression of the uncoupling protein genes 1, 2, or 3.
Notable changes in mitochondrial shuttle genes were down
regulation of both mitochondrial glycerol-3-phosphate dehydro-
genase 2 (GPD2) and cytosolic malic enzyme 1 (ME1). ATP citrate
lyase (ACLY), a cytosolic gene important for the production of
acetyl CoA was clearly downregulated. These enzymes are
thought to be important for GSIS [12,34].
MacDonald et al recently reported reduced expression of
GPD2 and ACLY in isolated islets from subjects with T2D [12],
which agrees with our findings. They also found reductions in
isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), propionyl
Coenzyme A carboxylase, beta polypeptide (PCCB), malate
dehydrogenase 2, NAD (mitochondrial, MDH2) and 3-oxoacid
CoA transferase 1 (OXCT1). None of these changes were
confirmed in our study.
These data may provide some clues to the mechanisms
responsible for glucotoxicity. We have extensively studied changes
of islet gene expression 4 wk after 90% pancreatectomy in rats and
found marked changes in glucose metabolism genes [26,35–37].
The general trend was that genes highly expressed in beta-cells
such as GLUT2 and GCK were downregulated while normally
suppressed genes such as LDHA were upregulated. There was
only some agreement between these and the present data. The
combined rodent and human data provide a valuable partial
picture, but the ideal study remains to be done to better
understand beta-cells in T2D. Results obtained with isolated islets
from cadaver donors have their limitations. LCM is an important
advance, but the amplification step brings potential artifact and
arrays of the future will provide better information. Other
weaknesses of the present approach are the serious illness of the
donors prior to death and the pancreases being subjected to hours
of cold ischemia time. We tried to exclude a history of premorbid
hyperglycemia in the nondiabetic controls, but with the use of
steroids, and the presence of brain damage and stress, there may
been periods of hyperglycemia that could have caused some
glucotoxicity changes. A goal for the future should be to obtain
pancreatic tissue from well-characterized patients at surgery.
Frozen sections can be subjected to LCM, and enough RNA
should be obtained to avoid the amplification step.
Lipid metabolism
With regard to lipid metabolism (Table S1), fatty acid synthase
(FASN) expression was modestly upregulated. It is interesting that
L-3-hydroxyacyl-Coenzyme A dehydrogenase (HADH), short
chain, which is part of the beta oxidation pathway in
mitochondria, was downregulated because mutations in this gene
have been linked to hyperinsulinemic hypoglycemia [38]. Another
downregulated gene of potential interest was stearoyl-CoA
desaturase (SCD), which contrasts with the increase found in
Zucker fatty (ZF) rats after partial pancreatectomy [39].
Channels and adrenergic receptor
In the evaluation of channels important for GSIS (Table S1),
KIR6.2 (KCNJ11) had weak signal strength and no differential
expression, but SUR1 was highly expressed and downregulated in
diabetes. The Calcium channel, voltage-dependent, L type, alpha
1D subunit (CACNA1D) was also downregulated. Inositol 1,4,5-
triphosphate receptor, type 3 (ITPR3), which could be important
for inducing calcium release, was downregulated. Potassium
voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1),
which acts to repolarize cells, was clearly upregulated in the
samples from diabetic subjects. Another change that could
influence secretion is downregulation of the adrenergic, alpha-
2A-, receptor (ADRA2A) that mediates the adrenergic suppression
of insulin secretion [40].
Exocytosis
Reports of downregulation of exocytosis molecules and gene
expression in islets from human T2D and GK rats, include
syntaxin-1A, SNAP-25, VAMP-2, nSec1 (Munc18), Munc 13-1,
synaptotagmin V and synaptophysin [11]. However, in our study
(Table S2), syntaxin 1A (STX1A), synaptobrevin 2 (VAMP2),
cellubrevin (VAMP3), Synaptophysin (SYP) and Syntaxin binding
protein 1 (STXBP1, Munc18-1) had high signal strength but no
differential expression. Synaptobrevin 1 (VAMP1) had much
lower signal strength. Synaptosomal-associated protein, 25 kDa
(SNAP25) was modestly downregulated and Unc-13 homolog B
(C. elegans) (UNC13B) was clearly downregulated. Synaptotag-
min V (SYT5) had little signal strength but Synaptotagmin IV
(SYT4) was highly expressed. Both N-ethylmaleimide-sensitive
factor (NSF) and N-ethylmaleimide-sensitive factor attachment
protein, alpha SNAP (NAPA) were highly, but not differentially,
expressed.
Insulin signaling
In contrast to the findings of Gunton et al that were performed
with isolated islet preparations of variable purity from subjects with
T2D [8], we found increased expression of the insulin receptor
(INSR) and the insulin-like growth factor receptor (IGF1R) in the
beta-cell tissue from T2D (Table S1). Increased expression was also
found for inositol polyphosphate-5-phosphatase (INPP5D, SHIP1)
and inositol polyphosphate phosphatase-like 1 (INPPL1, SHIP2).
Other upregulated genes included v-Ha-ras Harvey rat sarcoma
viral oncogene homolog (HRAS) and v-raf-1 murine leukemia viral
oncogene homolog 1 (RAF1). Of note, Forkhead box 01 (FOXO1)
was downregulated. The AKTs, 1, 2 and 3 all had strong but no
differential expression.
Human Beta Cell Gene Profile
PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11499ARNT, ARNT2 and HNF-1alpha
A major decrease in the expression of aryl hydrocarbon receptor
nuclear translocator (ARNT) was reported in isolated islets of T2D
subjects by Gunton et al [8]. This decrease was accompanied by
reductions in HIF 1 alpha (HNF1A), the insulin receptor (INSR),
several glycolytic enzymes including glucose-6-phospate isomerase
(GPI), phosphofructokinase (PFK), aldolase (ALDO), and phos-
phoglucomutase (PGM). We had good to excellent signal strength
for all of these genes but found no differential expression, except
for an increase in ALDOB (Table S1). Gunton et al also reported a
decrease in HNF4 alpha, but our signal strength for this gene was
too low to be meaningful.
Cell cycle genes
There were few changes of significance in the expression of cell
cycle genes (Table S2). Of the cyclins, cyclin D2 (CCND2) and D3
(CCND3) were the most highly expressed, but there was no
differential expression. Of the cyclin-dependent kinases, CDK4
and CDK6 were more highly expressed than CDK2. Of the cell
cycle inhibitors, only two tended to be upregulated, p16 (INK4a),
p,0.06, and p21 (Cip1). There were no changes of the E2F family
transcription factors. Retinoblastoma 1 (RB1) and RBL2:
retinoblastoma-like 2 (RBL2, p130) were well expressed but not
differentially. The signal for retinoblastoma-like 1 (RBL1, p107)
was very weak. Of interest, the CDK5 regulatory subunit
associated proteins (CDK5RAP) 1, 2 and 3 were all differentially
upregulated. They have been associated with neuronal develop-
ment and spindle check point function [41]. Because so much of
cell cycle control is exerted at the posttranslational level, these few
modest changes in gene expression must not be over interpreted.
The suggestion of change for p16 and p21 need to followed up;
p16 in particular appears to be an important marker of aged cells
that have restricted capacity for regeneration [42]. There has been
interest in the epigenetic control of replication [43], but there was
no differential expression of the following candidate genes EZH2,
MLL, PRC1, JMJD3, or BMI1.
ER stress
The ER stress genes were notable for their lack of change (Table
S3). The few changes of interest included some mannosidases;
isoforms MAN1B1 and MAN2B2 were upregulated. ER degra-
dation enhancer, mannosidase alpha-like 3 (EDEM3) was
downregulated. Endoplasmic oxidoreductin-1-like protein B
(ERO1LB) was highly expressed and downregulated. Endoplasmic
reticulum protein 27 kDa (ERP27), a noncatalytic member of the
protein disulfide isomerase, was modestly upregulated as were
DnaJ (Hsp40) homolog, subfamily C, member 3 (DNAJC3) and
protein disulfide isomerase family A, member 4 (PDIA4).
Other genes that were highly expressed and had no change
included: X-box binding protein 1 (XPB1), activating transcription
factor 6 (ATF6), eukaryotic translation initiation factor 2A (EIF2A),
UDP-glucose ceramide glucosyltransferase-like 2 (UGCGL2), DNA-
damage-inducible transcript 3 (DDIT3, CHOP), heat shock 70 kDa
protein 5 (HSPA5, BIP), heat shock protein 90 kDa beta (Grp94),
member 1 (HSP90B1), and mitogen-activated protein kinase 8
(MAPK8, JNK). Wolfram syndrome 1 (WFS1), the loss of which
leads to apoptosis of beta cells through ER stress [44], was highly, but
not differentially, expressed.
There has been great interest in the possibility that ER stress
contributes to the loss of beta-cells in T2D, and data indicate that
parts of the process are activated in beta-cells of people with T2D
[45–47]. One must be cautious about interpreting data from
isolated islets because of the trauma of isolation, which could
influence the expression of ER stress genes. It is possible that our
own data was influenced by severe premorbid illness of the
cadaver donors. One must remember that the unfolded protein
response of ER stress has a number of features that protect cells
from excessive demand for folding [48], so it is possible that the
few changes we found were beneficial.
Apoptosis
There was no differential expression of the major genes
implicated in apoptosis (Table S3). These include the anti-
apoptotic genes B-cell CLL/lymphoma 2 (BCL2) and BCLX,
and the pro-apoptotic genes BAD, BAK1, BAX and BIM. FAS
had very low signal strength and was upregulated with the probe
set (g4507582_3p_a_at) covering the 10%, and recognizing the 39
end of the transcript. Likewise, no changes were found for caspases
3, 6 or 7.
With regardtootherdeathmechanisms,genesfoundupregulated
in a study using isolated human islets exposed to cytokines were
BIRC3, BCL2A1, TNFAIP3, CFLAR [49] – most were unchanged
in ours but other interesting gene changes were found. In particular,
survivin (BIRC5) was modestly upregulated, although with a less
specific probe set. Survivin enhances proliferation and survival of
cancer cells and seems to have similar effects upon beta-cells [50].
Other upregulated genes that could be important are TRAF3,
TRADD and TRAF7. Interestingly, BOK and TRAF3IP2 were
downregulated.
Oxidative stress
Expression of some key genes related to oxidative stress are
shown in Table S3. The antioxidant thioredoxin (TXN) was
highly expressed and downregulated. The mitochondrial thior-
edoxin 2 (TXN2), which regulates mitochondrial membrane
potential and protects against oxidant-induced apoptosis [51] was
upregulated with a probe set with weaker signals but not with a
probe set with stronger signals. Thioredoxin interacting protein
(TXNIP), which in models of diabetes is overexpressed and seems
to have deleterious effects on beta-cells [52], was strongly but not
differentially expressed. Likewise, thioredoxin reductase 1
(TXNRD1), which may enhance ROS generation [53], was not
differentially expressed.
Other genes thought to be important for protection against
oxidative stress [54] were not differentially regulated including the
glutathione peroxidases 3 and 4 (GPX3,GPX4) and catalase.
Heme oxygenase 1 (HMOX1) was not different and had a weak
signal. The mitochondrial superoxide dismutase 2 (SOD2) was
upregulated; the extracellular form of superoxide dismutase 3
(SOD3) was as well but less significantly.
There were notable changes in the expression of a variety of
metallothionein genes with a number being clearly upregulated
and others tending in that direction. These include the
metallothioneins 1E, 1G, 1M, 1X and 2A. In addition,
metallothionein 1 pseudogene 2 was upregulated. Metallothione-
ins are involved in the regulation of metal metabolism, especially
zinc, which is important for insulin biosynthesis and storage, and
they have potent antioxidant effects because their cysteine residues
can capture harmful oxidant radicals [55]. Their expression can be
increased with oxidative stress.
Another interesting highly expressed downregulated gene is
protein phosphatase 1E (PPM1E, PP2C domain containing),
which is a member of a family implicated as negative regulators of
cell stress response pathways and cell growth [56]. In summary,
these data, taken in their entirety, suggest that beta-cells in T2D
are chronically subjected to oxidative stress. Other changes of
interest were up regulation of GADD45 variants, which contribute
to DNA repair and are upregulated by the stress of growth arrest.
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Data on inflammation from this study have been reported in
earlier publications [57,58].
Regeneration
A variety of genes potentially involved in pancreatic islet
development and regeneration were evaluated (Table S3). Genes
belonging to the regenerating islet gene (REG) family were
upregulated in samples of T2D subjects (Table S3); among them,
REG1A and REG3G were those with the highest differential
expression, and REG3G was the gene with the highest expression
variability among diabetic subjects (Table S3). The expression of
REG1A, REG1B, REG3A, and REG3G was quantified by real-
time PCR, performed on samples from four T2D subjects and four
controls, which, confirmed the differential expression between the
two groups (Fig. 3 A–D). The roles of Reg family of proteins
continue to be intriguingbutpoorly understood. Regwas first found
in the islets after partial pancreatectomy in rats [59]. Reg1 has been
implicated in beta-cell growth by association and by administration
of the peptide [60], and a knock-out resulted in reduced islet mass
[61]. Reg has also been found in beta-cells in mice with new onset
type 1 diabetes [62]. Reg3A (HIP/PAP) is expressed in multiple
Figure 3. Real-time PCR analysis of the regenerating islet genes Reg 1 alpha, Reg 1 beta, Reg 3 alpha, and Reg 3 gamma. The assay
was performed on samples from four T2D subjects (D) and four controls (C). Panels A–D show the relative gene expression of each single sample. In
panels a–d data are reported as mean 6 SE ratios of relative expression values from T2D samples (D) over values from control samples (C). The
statistical significance was evaluated by the two-tailed Student’s t-test using the dCt values (not performed with Reg 3 alpha and Reg 3 gamma since
the expression was not detectable in two control samples each).
doi:10.1371/journal.pone.0011499.g003
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found to have mitogenic and anti-apoptotic functions [63]. The
peptides human proIslet peptide (HIP) and islet neogenesis
associated protein (INGAP) are related to sequences in REG3A,
and are candidates for inducing neogenesis [64]. We also found that
the transcription factor SOX9 was upregulated in samples from
T2D donors (Table S3), and this differential expression of SOX9
wasconfirmed byreal-timePCR(Fig.4 A).Thisfindingisofinterest
because SOX9 is known to be present in pancreatic duct cells and
has been implicated in islet development by maintaining pancreatic
progenitors [65]. The metalloproteinase MMP7 was upregulated in
samples of T2D subjects (Table S3). The real-time PCR performed
in samples obtained from four T2D subjects and four controls
confirmed the differential expression of MMP7 between the two
groups (Fig. 4 B). MMP-7 is involved in development, cancer
invasion and sending epithelial signals to stromal cells [66,67].
Other growth and development genes
Because of indications of a regeneration process taking place,
WNT signaling genes were examined (Table S2). Most of the
WNT genes had no differential regulation except for down
regulation of WNT6. Of interest, dishevelled (dsh homolog 2,
DVL2), which is linked to WNT signaling and expressed in some
cancers [68], was upregulated. In addition, dickkopf homologs
(DKK) 3 and 4, which are important for development [69], were
upregulated. Another upregulated gene was sulfatase 1 (SULF1),
which is important for development and survival [69]. Frizzled
homolog 4 (FZD4) was downregulated. Secreted frizzled-related
proteins (SFRP) 2 and 5 were upregulated. We have previously
found increases of SFRP expression in differentiating human
pancreatic duct cells in vitro [70]. There was no differential
expression of transcription factor 7-like 2 (TCF7L2).
Notch signaling is important for differentiation of pancreatic
precursor cells to islet cells [27]. There was no differential
expression of notch 1, 2 and 3; notch 3 was most highly expressed
(Table S2). There was, however, a large differential increase of
notch homolog 2 (Drosophila) N-terminal like (NOTCH2NL). No
differential expression was found with delta-like (DLL) 1, 3 or 4,
nor of delta-like 1 homolog (DLK1, pref1), but this was very highly
expressed. Jagged 1 (JAG1) was not differentially expressed, but
jagged 2 (JAG2) was upregulated. Hairy and enhancer of split 1
(HES1) showed no difference, nor did presenilins (PSEN) 1 and 2,
or MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransfer-
ase (MFNG, manic fringe).
A variety of other genes have been suggested to be involved in
islet development [70]. There was downregulation of SMAD3 and
SMAD5, which are downstream targets of TGF beta. There was
modest upregulation of BMP1, isoform 3, and BMP5. Other
downregulated genes included cellular retinoic acid binding
protein 1 (CRABP1) and ubiquitin carboxyl-terminal esterase L
(UCHL) 1 and 3. BAMBI, which functions as a negative regulator
of TGF-beta signaling during development [71], was upregulated.
Inhibin, beta E (INHBE), a member of the activin beta family, is
thought to be involved in pancreatic exocrine cell growth and
proliferation [72] and was upregulated as was LASS1, a member
of the TGF-beta superfamily, involved in cell growth and
differentiation [73].
Endothelin 3 (EDN3) was very highly expressed but markedly
downregulated in T2D, while the expression of its receptor
(EDNRB) was unchanged. This secreted factor was found to
enhance proliferation and survival of intestinal goblet cells [74].
Ephrin-A3 (EFNA3) was upregulated, which is of interest because
this tyrosine kinase, has been found play a role in development and
also influence insulin secretion [75].
Tumor suppressors
We wondered if there were a regeneration process that was held
in check by increased expression of tumor suppressors (Table S2).
However, there was no differential expression of RB1, TP53,
PTEN or APC. Other genes have been found to suppress
Figure 4. Real-time PCR analysis of Sox9 and matrix metalloproteinase 7 (MMP7) genes. The assay was performed on samples from four
T2D subjects (D) and four controls (C). Panels A–B show the relative gene expression of each single sample. In panels a–b data are reported as
mean 6 SE ratios of relative expression values from T2D samples (D) over values from control samples (C). The statistical significance was evaluated
by the two-tailed Student’s t-test using the dCt values.
doi:10.1371/journal.pone.0011499.g004
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TIMP2 and BRCA1; none were differentially changed.
Genes associated with type 2 diabetes
Recent genome wide association studies (GWAS) have identified
a number of gene loci associated with type 2 diabetes, many of
which are related to beta-cell function or development [7]. As
shown in Table 2, the genes with upregulated expression include:
IGF2BP2, TSPAN8, and HNF1B (TCF2). Downregulated
expression was found for JAZF1 and SLC30A8. Then there were
genes with clear signal strength and little to no suggestion of
differential expression: CDKAL1, TCF7L2, CDKN2A/2B, FTO,
WFS1, THADA, ADAMTS9, HHEX, IDE, and CDC123.
Finally there were genes with little or no expression: CAMK1d
NOTCH2, KCNJ11, MC4R, and PPARG. While these data are
unique, it is not clear whether the genes with differential
expression have pathophysiological importance. Some of the gene
polymorphisms must cause problems with function and develop-
ment, but there is no particular reason to have expected their level
of expression to be altered in this group of non-genotyped subjects.
Functional and ontologies gene sets analysis
After collapsing of the probe sets by using the gene symbols,
20,648 genes were selected; out of these genes, 9,718 (47.1%) were
markers of the control phenotype and 10,930 (52.9%) were
markers of the T2D phenotype. Using the phenotype-based
permutation on the functional gene set analysis (C2 collection,
canonical pathways, chemical and genetic perturbations), two gene
sets were found enriched in samples obtained from T2D subjects
and one was enriched in samples from non-diabetic controls
(Table S4). In the C5 GO Biological Process collection, 13 gene
sets were enriched in samples from T2D subjects and 5 were
enriched in samples from controls (Table S4). In the GO
Molecular Function and GO Cellular Component, 7 gene sets
and 3 gene sets were respectively enriched in beta-cell samples
from T2D subjects (Table S4). Changes of particular interest
include three sets indicating altered JNK activity, which may have
implications for susceptibility to apoptosis. Also noteworthy was
the differential expression of fatty acid oxidation pathways,
especially considering the findings linking altered fat metabolism
with insulin secretory dysfunction [39].
Summary
These data provide unique new information about gene
expression in beta-cells of subjects with T2D. Some of the results
obtained previously from preparations of isolated human islets
agree with ours, but much does not, which is not surprising
considering the lack of purity of these samples and the trauma to
which they were exposed. Our approach also has some drawbacks,
but the use of LCM on frozen sections eliminates many for the
artifacts of islet isolation. Some changes were found in genes
implicated in glucotoxicity, which complement existing rodent
data, but the premorbid illness of the subjects may have obscured
changes that might have been found with pristine specimens that
might be obtained by either surgery or biopsy.
Little was found in genes associated with beta-cell replication
and death, including the categories of cell cycle, apoptosis and ER
stress. An important point is that there is heterogeneity in beta-
Table 2. Gene expression of molecules associated with type 2 diabetes according to genome wide association studies (7).
Probe ID Gene symbol Ctrl T2D LCB p value
Genes associated with Type 2 Diabetes
g5729883_3p_at IGF2BP2 53±67 9 ±8 1.2 0.017
g4759237_3p_at TSPAN8 67±8 101±11 1.2 0.026
g4507396_3p_at HNF1B 102±5 123±5 1.1 0.011
Hs.5437.2.A2_3p_at JAZF1 122±13 76±7 21.3 0.008
Hs.170042.0.A1_3p_at SLC30A8 3608±223 2818±118 21.1 0.007
214877_3p_at CDKAL1 88638 5 65 20.9 0.670
Hs.173638.0.S3_3p_at TCF7L2 1111672 1112677 0.9 0.995
g4502748_3p_at CDKN2A 317632 426644 1.1 0.060
g11386206_3p_a_at CDKN2B 25622 6 62 0.9 0.686
g1710215_3p_at FTO 2429661 2494658 1.0 0.448
g13376995_3p_at WFS1 981675 1145690 1.0 0.178
4864673C_3p_s_at THADA 354618 391619 1.0 0.167
Hs.16450.0.A1_3p_at ADAMTS9 24662 9 67 0.6 0.587
g10835016_3p_at HHEX 42611 4168 20.5 0.933
Hs.1508.0.S2_3p_at IDE 80676 7 65 21.0 0.184
g5174422_3p_at CDC123 68676 3 65 20.9 0.577
Hs.47883.0.A1_3p_at CAMK1D 20622 1 63 0.8 0.585
g11275977_3p_a_at NOTCH2 20621 7 61 21.0 0.070
Hs.248141.0.S1_3p_at KCNJ11 21632 2 61 0.8 0.960
g5174532_3p_at MC4R 7615 61 21.0 0.110
g7705548_3p_a_at PPARG 11611 1 61 20.9 0.673
Data are expressed as mean 6 SE (standard error of the mean) of transcript array signals of control samples and samples from type 2 diabetic subjects. Differentially
expressed genes as for the lower confidence bound (LCB) (1.2) and/or the p value (p,0.05) are in bold. Ctrl: Control subjects; T2D: Type 2 diabetic subjects.
doi:10.1371/journal.pone.0011499.t002
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division and death might be a small minority of the population.
This fits the small number of beta-cells immunostained for CHOP
(DDIT) in T2D islets [47]. Thus, it is easy to see how relevant
changes of gene expression in a minority population could be
missed. It is of considerable interest that upregulation of a number
of metallothionein genes was found; the genes are known to be
sensitive to alterations in oxidative stress.
The changes in the expression of genes associated with
pancreatic regeneration were unexpected findings from the
samples of these subjects with T2D. There is little to support the
presence of active regeneration in T2D, but there may be a
process that is somehow activated and then arrested. These
findings certainly require further study.
Finally, differential gene expression was found in some of the
genes linked by GWAS studies to the pathogenesis of T2D. These
finding may contribute to the intense efforts currently underway to
understand how these genes make their contributions to the
development of T2D.
Methods
Ethics Statement
Tissue samples were obtained and records reviewed with IRB
approval from Partners Healthcare and Joslin Diabetes Center.
The study of the discarded human tissue and review of medical
records was considered exempt from informed consent by both of
these IRBs.
Tissue samples
Pancreas specimens from ten non-diabetic and ten T2D subjects
were studied. The pancreases from non-diabetic donors and two
pancreases from T2D subjects were obtained from the New
England Organ Bank and processed at the Joslin Diabetes Center.
Pancreas specimens of eight T2D subjects were obtained from the
University of Pisa. All the donors were White; the clinical
characteristics are reported in Table 1. All the samples were
processed using the same protocol. Pieces of pancreas were excised
from the body of the pancreas, placed in cryomolds, embedded in
Tissue-Tek OCT medium (Sakura Finetek U.S.A., Torrance, CA),
immediately frozen in chilled isopentane, and stored at 280uC,
pending sectioning at 8 mm [18].
Laser Capture Microdissection (LCM)
LCM was performed using a modified protocol for human
pancreatic tissue dehydration [18,19]. Frozen pancreatic sections
were fixed in 70% ethanol for 30 seconds, rinsed by 5 dips in
diethylpyrocarbonate (DEPC)-treated water and dehydrated in
100% ethanol twice for 1 min, and xylene for 4 minutes, the
sections were air-dried and LCM was performed using PixCell II
Laser Capture Microdissection System (Arcturus Engineering,
Mountain View, CA). LCM was performed by melting thermo-
plastic films mounted on transparent LCM caps (Arcturus) on
beta–cells, identified by their intrinsic autofluorescence, in islets
with no signs of amyloidal deposits. For the smallest spot size, the
system was set to the following parameters: 35 mW the laser
power, 2.5 msec the pulse duration and 7.5 mm the spot size. The
thermoplastic film containing the microdissected cells was
incubated with 10 ml of guanidine thiocyanate and polyethylene
glycol octylphenol ether-based buffer (Buffer RLT, Qiagen,
Valencia, CA), for 30 minutes at 42uC. Each microdissection
session was performed in 15–20 min during which no more than 3
pancreatic sections were processed; each section typically con-
tained 3–7 islets. LCM was performed on 20 pancreas sections
obtained from the control donors and on 20–30 sections obtained
from the diabetic subjects.
RNA extraction, amplification biotinylation and GeneChip
processing
Total RNA was extracted from each population of laser
captured beta–cells using a modified protocol for RNA micro-
isolation [76]. RNA was extracted using phenol-chloroform-
isoamyl alcohol and precipitated with sodium acetate and
glycogen carrier in isopropanol. After initial recovery and
resuspension of the RNA pellet, genomic DNA contamination
was removed by incubation with 10 units of DNase I (GenHunter,
Nashville, TN) for 2 hours at 37uC, in presence of 10 units of
RNase inhibitor (Life Technologies, Inc., Gaithersburg, MD). The
treatment with DNase I was followed by RNA re-extraction and
precipitation. The pellet was resuspended and total RNA was
amplified by T7-based linear amplification using T7-oligo-dT-
primers. Two rounds of amplification were performed using
RiboAmp HS RNA Amplification Kits (Arcturus) [18,19].
Amplified RNA (aRNA) quantity was evaluated spectro-photo-
metrically by readings at 260 nm (A260) and 280 nm (A280).
RNA quality was assessed by running 100 ng of aRNA on Nano
LabChip of Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.,
Santa Clara, CA). Amplified RNA (1 mg) was converted into
double-stranded complementary DNA (cDNA) using the Ri-
boAmp HS RNA Amplification Kit (Arcturus), and biotinylated
complementary RNA (cRNA) was generated from cDNA by in
vitro transcription reaction using the BioArray High Yield RNA
Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY).
RNA products were purified using the MiraColTM Purification
Columns (Arcturus). RNA extraction and amplification yielded
aRNA with A260:A280 ratios of 2.3. The RNA integrity number
(RIN) was 2.3 for most of the samples.
Biotinylated cRNA was fragmented to nucleotide stretches of
30–200 nucleotides and hybridized to the GeneChip Human X3P
Array (Affymetrix, Santa Clara, CA). The Affimetrix X3P chip
contains 61,359 probe sets representing 47,000 transcripts and
variants, including approximately 38,500 well-characterized
human genes. The probe arrays were washed and stained using
the Fluidics Station 400 and scanned using the Affymetrix Gene
Chip Scanner 3000 (Gene Chip Expression Analysis Technical
Manual, Affymetrix). Microarray experiments of four samples from
T2D subjects and four samples from non-diabetic controls were
run at the Genomics Core facility of the Massachusetts General
Hospital, the remaining microarrays, six samples from diabetic
subjects and six from non-diabetic controls were run at the
Genomics Core of the Joslin Diabetes Center. Principal compo-
nent analysis was performed by the Rosetta Resolver System
(Rosetta Biosoftware, Microsoft, Seattle, WA) to assess the
variation in the expression of genes among the different samples.
Microarray data analysis
Array data were normalized and comparisons were performed
using the DNA-Chip Analyzer (dChip) software (Harvard School of
Public Health, Boston, MA).dChip software implements invariant set
normalization and probe-level model-based expression analysis on
multiple arrays, and computes the t-statistic and the p-value based on
the t-distribution. Computation of standard errors for expression
indexes allows calculating confidence intervals for fold changes
[77,78]. Lower confidence bound (LCB) and p-value were used to
assess differentially expressed genes; cutoffs of 1.2 for LCB and
p,0.05 are often used. Hierarchical clustering was performed using
dChip software. Principal component analysis was performed by the
Rosetta Resolver System (Rosetta Biosoftware, Microsoft, Seattle,
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different samples. Changes in the expression of functionally related
genes at the genome-wide expression profile level were detected using
Gene Set Enrichment Analysis (GSEA, versions 2 and 2.5, Broad
Institute, Cambridge, MA). For the analysis, genes represented by
more than one probe were collapsed to the probe with the maximum
value using the gene symbols [79]. Genes were ranked based on
values estimated by Affymetrix Micro Array Suite (MAS) 5.0 and
scaled to the value of 1500. Functional (C2 collection: 1456 gene sets)
and gene ontology (GO) (C5 collection: 825 Biological Process
Ontology gene sets, BP; 396 Molecular Function Ontology gene sets,
MF; 233 Cellular Components Ontology gene sets, CC) gene sets,
restricted to a minimum of 15 and a maximum of 1000 gene set size,
were analyzed. A nominal p-value,0.01 at multiple hypothesis
testing false discovery rate (FDR)#25% was used as parameter to
detect differentially regulated gene sets.
Quantitative analysis of selected transcripts by real-time
PCR
PCR measurements of selected transcripts using amplified RNA
were determined on samples from four T2D subjects and four
non-diabetic controls. cDNA templates were synthesized from
1 mg of aRNA using TaqMan Reverse Transcription Reagents
(Applied Biosystems). TaqMan Universal PCR Master Mix
(Applied Biosystems) was used to perform real-time PCR in the
presence of 0.2 ng cDNA, 1 mM primers and 0.25 mM probe in a
total volume of 20 ml. The housekeeping gene ribosomal protein
L32 (RPL32) transcript was used as a reference. Primers and
probes were designed using Primer Express software (Applied
Biosystems) and were purchased from MWG-Biotech Inc. (MWG-
Biotech Inc., High Point, NC). Primers and probe sequences are
reported in Table 3. Quantitative analysis of gene expression was
performed using the Applied Biosystems 7300 Real Time PCR
System (Applied Biosystems). For each sample, triplicate amplifi-
cations were performed and average measurements were taken for
data analysis. The N-fold differential expression was assessed by
2
2DDCT method and the statistical significance was evaluated by
the two-tailed Student’s t-test using the dCt values.
Data analysis
Data are expressed as mean (M) 6 standard deviation (SD) or
standard error of the mean (SE), as indicated. The two-tailed
Student’s t-test was used to compare data from pancreas donors.
Supporting Information
Table S1 Gene expression of molecules involved in glucose and
lipid metabolism, and beta-cell channels structure and function,
and of the adrenergic receptor, insulin signaling molecules,
ARNT, ARNT2 and HIF1A.
Found at: doi:10.1371/journal.pone.0011499.s001 (0.09 MB
DOC)
Table S2 Gene expression of hormones, receptors, transcription
factors, and molecules involved in exocytosis, cell cycle, WNT and
Notch signaling, TGF-beta signaling and tumor suppression.
Found at: doi:10.1371/journal.pone.0011499.s002 (0.15 MB
DOC)
Table S3 Gene expression of molecules involved in ER stress,
apoptosis, oxidative stress, islet development and regeneration.
Found at: doi:10.1371/journal.pone.0011499.s003 (0.11 MB
DOC)
Table S4 GSEA results with FDR#0.25.
Found at: doi:10.1371/journal.pone.0011499.s004 (0.08 MB
DOC)
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Table 3. Primers and probes used for real-time PCR.
Transcript GeneBank no. Primer Primer sequence (59-39) Probe sequence (59-39)
REG1A NM_002909 F CCTCCATGACCCCAAAAAGA CGCCGCTGGCACTGGAGCA
R AATGCCCCAGGACTTGTAGGA
REG1B NM_006507 F GGTCCTGCAATTACTATGAAGTCAAA CTCCAACTCAGTTCAGACCATCTCCTCCC
R AAGATCAGCGATGCAAACTCATT
REG3A NM_002580 F GGTTACCCTATGTCTGCAAGTTCA TGACTAGTGCAGGAGGGAAGTCAGCAGC
R GATGAGTTGCACACCAAACACA
REG3G NM_001008387 F CCCCACACAGGGCTCTGA CCTGATGGAGATGGATGGGAGTGGAG
R CCATGCAAAGTAATTCATCACATCA
SOX9 NM_000346 F CCACTGATTGGCCACAAGTG AATGCGCTTGGATAGGTCATGTTTGTGTC
R GCAACTCGTACCCAAATTTCCA
MMP7 NM_002423 F TGTATGCTGCAACTCATGAACTTG CCATTCTTTGGGTATGGGACATTCCTCTG
R AGGTTGGATACATCACTGCATTAGG
RPL32 NM_000994 F CTGGCCATCAGAGTCACCAA CCCAATGCCAGGCTGCGCA
R TGAGCTGCCTACTCATTTTCTTCA
Primers and probes were designed using Primer Express software (Applied Biosystems); the oligonucleotide sequences for forward (F) and reverse (R) primers and the
probe were designed within 20–200 bases close to the 39 end of the transcript with one of the primers or the probe spanning two adjacent exons.
doi:10.1371/journal.pone.0011499.t003
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